REGULAR CONTENT
Final ID
596
Type
Educational Exhibit-Poster Only
Authors
C Gadens Zamboni1, J Green1, L Higgins2
Institutions
1Johns Hopkins University School of Medicine, Baltimore, MD, 2WVU Medicine, Morgantown, WV
Purpose
1) To contextualize utilization of nanomedicines and stem cells to treat peripheral arterial disease (PAD) 2) To summarize delivery vehicles, therapeutic targets and routes of delivery that may be applied to treat PAD in an effort to improve amputation free survival 3) To present an overview of preclinical and clinical findings on nanoscale therapy for PAD 4) To discuss the applicability of nanomedicines and stem cells in the treatment of PAD.
Materials & Methods
PAD is one of the most common complications of atherosclerosis and is estimated to affect 12-20% of the population >65 years of age in the US.1,2 Currently, endovascular interventions play a critical role in the treatment of PAD. However, patients with critical limb ischemia are often confronted with few options for revascularization. These patients may benefit most from the application of nano-based gene/stem cell therapies designed to promote robust angiogenesis.
Results
:Over the past twenty years, new therapeutic agents and targets have been exploited for the treatment of PAD. Pro-angiogenic genes and proteins are among the chief therapeutic targets. As important as the therapeutic agent, the delivery vehicle is also critical to treatment response. Nanoparticles (NPs) are emerging as a promising technology for the treatment of PAD; they can be optimized for passive targeting and/or tuned with PAD-specific ligands to direct therapy to the disease site. Stem cells, genetically engineered to express pro-angiogenic genes, have been exploited as delivery vehicles to treat cancer3 and in regenerative medicine. The application of stem cells to induce angiogenesis has been successful in preclinical studies4 and has the potential to become an alternative for PAD patients. Unfortunately, few nanomedicine-based platforms have made it to clinical trials. Here we also aim to delineate possible reasons for suboptimal results from prior clinical studies.
Conclusions
Endovascular interventions have the potential to become the preferred method of delivery for theranostics designed to treat PAD. Future work is required to optimize and design nanoscale therapeutics to provide robust neovascularization for patients who face the grim prospect of limb amputation.
Final ID
596
Type
Educational Exhibit-Poster Only
Authors
C Gadens Zamboni1, J Green1, L Higgins2
Institutions
1Johns Hopkins University School of Medicine, Baltimore, MD, 2WVU Medicine, Morgantown, WV
Purpose
1) To contextualize utilization of nanomedicines and stem cells to treat peripheral arterial disease (PAD) 2) To summarize delivery vehicles, therapeutic targets and routes of delivery that may be applied to treat PAD in an effort to improve amputation free survival 3) To present an overview of preclinical and clinical findings on nanoscale therapy for PAD 4) To discuss the applicability of nanomedicines and stem cells in the treatment of PAD.
Materials & Methods
PAD is one of the most common complications of atherosclerosis and is estimated to affect 12-20% of the population >65 years of age in the US.1,2 Currently, endovascular interventions play a critical role in the treatment of PAD. However, patients with critical limb ischemia are often confronted with few options for revascularization. These patients may benefit most from the application of nano-based gene/stem cell therapies designed to promote robust angiogenesis.
Results
:Over the past twenty years, new therapeutic agents and targets have been exploited for the treatment of PAD. Pro-angiogenic genes and proteins are among the chief therapeutic targets. As important as the therapeutic agent, the delivery vehicle is also critical to treatment response. Nanoparticles (NPs) are emerging as a promising technology for the treatment of PAD; they can be optimized for passive targeting and/or tuned with PAD-specific ligands to direct therapy to the disease site. Stem cells, genetically engineered to express pro-angiogenic genes, have been exploited as delivery vehicles to treat cancer3 and in regenerative medicine. The application of stem cells to induce angiogenesis has been successful in preclinical studies4 and has the potential to become an alternative for PAD patients. Unfortunately, few nanomedicine-based platforms have made it to clinical trials. Here we also aim to delineate possible reasons for suboptimal results from prior clinical studies.
Conclusions
Endovascular interventions have the potential to become the preferred method of delivery for theranostics designed to treat PAD. Future work is required to optimize and design nanoscale therapeutics to provide robust neovascularization for patients who face the grim prospect of limb amputation.